Detalhe da pesquisa
1.
Systematic literature review of efficacy and safety of first-line maintenance therapy trials in advanced ovarian cancer.
Future Oncol
; 18(30): 3435-3447, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-36102225
2.
Budget impact analysis of niraparib for first-line maintenance therapy in advanced ovarian cancer from a US payer perspective.
J Manag Care Spec Pharm
; 27(10): 1377-1387, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34595950
3.
Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.
Pharmacoeconomics
; 37(3): 391-405, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30478649
4.
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
J Clin Oncol
; 37(34): 3183-3191, 2019 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31518175
5.
Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.
Pharmacoeconomics
; 37(7): 965-967, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044349